-
Mashup Score: 2
A biologics license application was submitted to the FDA seeking the approval of RP1 plus nivolumab for patients with PD-1 inhibitor–exposed melanoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
A biologics license application was submitted to the FDA seeking the approval of RP1 plus nivolumab for patients with PD-1 inhibitor–exposed melanoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Accelerated Approval Sought for RP1 Plus Nivolumab in Advanced Melanoma #melsm #oncology https://t.co/JDDY31u9Xs
-
-
Mashup Score: 3Bel-Sar Generates Tumor Control, Preserves Visual Acuity in Early Choroidal Melanoma - 2 month(s) ago
First-line bel-sar displayed tumor control and preserved visual acuity in early-stage choroidal melanoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
First-line bel-sar displayed tumor control and preserved visual acuity in early-stage choroidal melanoma. #melsm #oncology https://t.co/huACxFIXBs https://t.co/1W2JNpdrvB
-
-
Mashup Score: 3Bel-Sar Generates Tumor Control, Preserves Visual Acuity in Early Choroidal Melanoma - 2 month(s) ago
First-line bel-sar displayed tumor control and preserved visual acuity in early-stage choroidal melanoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
First-line bel-sar displayed tumor control and preserved visual acuity in early-stage choroidal melanoma. #melsm #oncology https://t.co/huACxFIXBs https://t.co/1W2JNpdrvB
-
-
Mashup Score: 2Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma - 3 month(s) ago
The phase 3 IOB-013/KN-D18 trial of IO102-IO103 plus pembrolizumab in advanced melanoma will continue without modifications.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma #melsm #oncology https://t.co/NG7OrYOoI3
-
-
Mashup Score: 2Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma - 3 month(s) ago
The phase 3 IOB-013/KN-D18 trial of IO102-IO103 plus pembrolizumab in advanced melanoma will continue without modifications.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma #melsm #oncology https://t.co/NG7OrYOoI3
-
-
Mashup Score: 5
Adjuvant pembrolizumab did not have a significant impact on long-term HRQOL outcomes in patients with resected stage III melanoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Adjuvant Pembrolizumab Does Not Affect Long-Term HRQOL in Stage III Melanoma @EORTC @TheLancetOncol #melsm #oncology https://t.co/XZN9YTZjAj
-
-
Mashup Score: 1FDA Grants Fast Track Designation to VMT01 for Unresectable/Metastatic MC1R+ Melanoma - 3 month(s) ago
The FDA has granted fast track designation to the MCR1-targeted theranostic ligand VMT01 for unresectable or metastatic melanoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Grants Fast Track Designation to VMT01 for Unresectable/Metastatic MC1R+ Melanoma #melsm #oncology https://t.co/vdnJAY65Ho
-
-
Mashup Score: 2Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma - 3 month(s) ago
The phase 3 IOB-013/KN-D18 trial of IO102-IO103 plus pembrolizumab in advanced melanoma will continue without modifications.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma #melsm #oncology https://t.co/NG7OrYOoI3
-
-
Mashup Score: 5
Adjuvant pembrolizumab did not have a significant impact on long-term HRQOL outcomes in patients with resected stage III melanoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Adjuvant Pembrolizumab Does Not Affect Long-Term HRQOL in Stage III Melanoma @EORTC @TheLancetOncol #melsm #oncology https://t.co/XZN9YTZjAj
-
Accelerated Approval Sought for RP1 Plus Nivolumab in Advanced Melanoma #melsm #oncology https://t.co/JDDY31u9Xs